You are currently viewing Amgen Announces Third – party Data Breach Stemming from Incident at Sirva Relocation | Console and Associates , P . C .
Representation image: This image is an artistic interpretation related to the article theme.

Amgen Announces Third – party Data Breach Stemming from Incident at Sirva Relocation | Console and Associates , P . C .

The company has notified the affected individuals and is taking steps to mitigate the impact of the breach. The company is committed to protecting the privacy and security of its customers and is working closely with law enforcement and cybersecurity experts to investigate the incident and prevent future breaches. Amgen, Inc., a leading biotechnology company, recently encountered a significant security incident that has raised concerns about the protection of sensitive information. The company, which specializes in the development and commercialization of innovative therapies for serious and life-threatening diseases, discovered that confidential data belonging to certain individuals had been accessed by an unauthorized party.

Data breaches can expose sensitive personal information, such as social security numbers, credit card details, and medical records. This information can be used by cybercriminals to commit identity theft, financial fraud, or other illegal activities.

The company also provided a dedicated helpline for consumers to call for assistance. Sirva, a cybersecurity firm, undertook a meticulous review of the compromised files to ascertain the extent of the data leak. This involved identifying the specific information that was exposed and pinpointing the consumers who were potentially impacted by the breach. The firm’s thorough investigation was crucial in understanding the severity of the situation and formulating an appropriate response. In response to the data breach, Amgen took immediate action on September 24, 2024.

Enbrel, a TNF inhibitor, is used to treat rheumatoid arthritis, psoriasis, and ankylosing spondylitis. Neulasta, a granulocyte colony-stimulating factor (G-CSF), is used to stimulate the production of white blood cells in patients undergoing chemotherapy. Amgen’s pipeline includes several promising drugs, such as AMG 530, AMG 510, AMG 590, and AMG 531. AMG 530 is a PCSK9 inhibitor that lowers LDL cholesterol levels.

Leave a Reply